Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that a total of 5,113,904 securities had been repurchased prior to the latest trading day, with an additional 150,000 shares bought back on the previous day as part of the daily buy-back reporting.
This continued execution of the buy-back signals ongoing capital management efforts that may support earnings per share and potentially shareholder value by reducing shares on issue. The regular daily notifications also underline the company’s compliance with ASX disclosure requirements and give investors transparency on the pace and scale of the buy-back activity.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian pathology and medical diagnostics provider listed on the ASX under the code ACL. The company offers laboratory testing services, processing pathology samples for healthcare providers, hospitals and patients across Australia, positioning it within the broader healthcare and diagnostics industry.
Average Trading Volume: 687,392
Technical Sentiment Signal: Sell
Current Market Cap: A$426.6M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.